Skip to main content

Research Repository

Advanced Search

All Outputs (2)

H-IPSE is a pathogen-secreted host nucleus-infiltrating protein (Infiltrin) expressed exclusively by the Schistosoma haematobium egg stage (2017)
Journal Article
Pennington, L. F., Alouffi, A., Mbanefo, E. C., Ray, D., Heery, D. M., Jardetzky, T. S., …Falcone, F. H. (2017). H-IPSE is a pathogen-secreted host nucleus-infiltrating protein (Infiltrin) expressed exclusively by the Schistosoma haematobium egg stage. Infection and Immunity, 85(12), Article e00301-17. https://doi.org/10.1128/iai.00301-17

Urogenital schistosomiasis, caused by the parasitic trematode Schistosoma haematobium, affects over 112 million people worldwide. As with Schistosoma mansoni infections, the pathology of urogenital schistosomiasis is related mainly to the egg stage,... Read More about H-IPSE is a pathogen-secreted host nucleus-infiltrating protein (Infiltrin) expressed exclusively by the Schistosoma haematobium egg stage.

Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with Polycystic Ovary Syndrome (2017)
Journal Article
Atiomo, W., Shafiee, M. N., Chapman, C., Metzler, V. M., Abouzeid, J., Latif, A., Chadwick, A., Kitson, S., Sivalingam, V. N., Stratford, I. J., Rutland, C. S., Persson, J. L., Ødum, N., Fuentes-Utrillia, P., Jeyapalan, J. N., Heery, D. M., Crosbie, E. J., & Mongan, N. P. (2017). Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with Polycystic Ovary Syndrome. Clinical Endocrinology, 87(5), 557-565. https://doi.org/10.1111/cen.13436

OBJECTIVE: Women with a prior history of polycystic ovary syndrome (PCOS) have an increased risk of endometrial cancer (EC). AIM: To investigate whether the endometrium of women with PCOS possess gene expression changes similar to those found in EC.... Read More about Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with Polycystic Ovary Syndrome.